Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.70 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.70 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 1/20 | 0.70 |
| ▸ | MMP3 | P08254 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL29545414 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41884 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL2221981 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL3680869 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41883 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL28250743 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417256 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL497163 | 0.99 | TDP1 (0.69) | MMP2MMP3MMP7MMP8ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 103316 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146259-A1 | COMPOSITIONS AND SYSTMES FOR HERPES SIMPLEX VIRUS PACKAGING AND USES THEREOF | Opentrons LabWorks Inc. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4746704-A2 | METHODS FOR CRYOPRESERVING CELLS FOR MODELING A HUMAN BRAIN OR A HUMAN BLOOD-BRAIN BARRIER | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636293-B2 | Methods of treating charcot-marie-tooth disease | CMTX BIOTECH INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122076476-A | Yb-BiOI/Ce-MgAl-LDH composite photocatalyst and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12636371-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SKYBIO LLC (US) | 2026-05-26 | — | — | US | claimed |
| CN-122094672-A | Method for treating and preventing non-viral tick-borne diseases and symptoms thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260137644-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | XMK THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | US | claimed |
| EP-0091409-A1 | Pharmaceutical compositions containing carrageen | KabiVitrum AB (SE) | 1983-10-12 | — | — | EP | claimed |
| US-4409209-A | POTENTIATION OF ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1983-10-11 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4293539-A | Controlled release formulations and method of treatment | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| EP-0025698-A2 | Controlled release formulations | ELI LILLY AND COMPANY (US) | 1981-03-25 | — | — | EP | claimed |
| US-4126680-A | TETRACYCLINE ANTIBIOTIC COMPOSITIONS | PFIZER INC. (US) | 1978-11-21 | — | — | US | claimed |
| US-4086332-A | ANTIBIOTIC; WITH A MAGNESIUM COMPOUND AND 2-PYRROLIDONE IN WATER | PFIZER INC. (US) | 1978-04-25 | — | — | US | claimed |
| US-3966922-A | TETRACYCLINE, VITAMIN B(2), VANILLIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-06-29 | — | — | US | claimed |
| US-3957983-A | ANTIBIOTICS | INTELLECTUAL PROPERTY DEVELOPMENT CORPORATION (US) | 1976-05-18 | — | — | US | claimed |
| US-3957980-A | INJECTABLE ANTIBIOTICS | PFIZER INC. (US) | 1976-05-18 | — | — | US | claimed |